Dermatologicals in Japan - New Market Research Report

From: Fast Market Research, Inc.
Published: Wed Apr 01 2015

Retail value sales of dermatologicals in Japan increased by 2% in current value terms in 2014. Hair loss treatments continued to hold the largest value share of 26%. The category is led by RiUP by Taisho Pharmaceutical, supported by the research findings by the Japanese Dermatological Association that certified the effectiveness of the key active ingredient in RiUP. Hair loss treatments was largely affected by the tax hike in April 2014 because of its relatively high retail price and long shelf life. Consumers had rushed to purchase hair loss treatments before the retail price increased. While men’s hair loss treatments accounted for the majority of total sales, women’s hair loss treatments expanded its value share in 2014 with several new product launches. In addition to women in middle-age and above, an increasing number of young women in their 30s are using hair loss treatment products for prevention purposes.

Competitive Landscape

Taisho Pharmaceutical Co Ltd remained the top player in dermatologicals. Its brand RiUP continued to dominate hair loss treatments, with retail value share of 48% in 2014. The performance of RiUP in 2014 was largely affected by the tax hike in April 2014. Due to the high unit price of RiUP, many consumers purchased the brand by the end of March 2014. After the tax hike, the value sales of the brand dropped. Kao Corp’s Success ranked second. Compared to RiUP, Success is popular among younger consumers because of its affordable pricing. Other players actively promoted women’s hair loss treatments in 2014. Bathclin Corp launched Mouga L Molty Este Care Line from its hair loss treatments brand Mouga in August 2014. The newly launched cleansing oil and hair oil are intended for female consumers to enjoy the same positive effects on their hair as at beauty salons. RiUP also offers a hair loss treatment for women, RiUP Regenne, although its retail value sales remained low in 2014.

Full Report Details at

Industry Prospects

Dermatologicals is expected to register a marginal value CAGR at constant 2014 prices over the forecast period. Cold sore treatments is expected to continue to record the fastest growth but account for only 4% share of total retail value sales of dermatologicals in 2019. Retail value sales of hair loss treatments are expected to grow steadily, driven by growing demand among female consumers. More products marketed for female hair loss treatments are expected to be introduced over the forecast period. Given the low risk of side-effects in dermatologicals, private label is expected to increase its presence over the forecast period.

Report Overview

Discover the latest market trends and uncover sources of future market growth for the Medicated Skin Care industry in Japan with research from Euromonitor's team of in-country analysts.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Dermatologicals in France
- Dermatologicals in Thailand
- Dermatologicals in Israel
- Dermatologicals in Romania
- Dermatologicals in Brazil

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »